Per- and Polyfluoroalkyl Substances (PFAS) Exposures and COVID-19 Vaccine Effectiveness

全氟烷基物质和多氟烷基物质 (PFAS) 暴露与 COVID-19 疫苗的有效性

• 批准号: 10331097
• 负责人: Jefferey L. Burgess
• 金额: $ 26.11万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-16 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10331097
• 关键词: 19 year old; 2019-nCoV; Adult; Age; Alkanesulfonates; Antibodies; Antibody Response; Antibody titer measurement; Arizona; Blood; COVID-19; COVID-19 vaccination; COVID-19 vaccine; COVID-19 vaccine evaluation; Centers for Disease Control and Prevention (U.S.); Cessation of life; Chemicals; Child; Collection; Communicable Diseases; Control Groups; Coughing; Data; Diphtheria; Disease; Dose; Effectiveness; Emergency Care; Emergency response; Enrollment; Epidemiology; Ethnic Origin; Exposure to; FDA Emergency Use Authorization; Fever; Florida; Frequencies; Funding; Gender; General Population; Goals; Health; Health Personnel; Healthcare; Hispanics; Immune; Immune response; Individual; Infection; Ingestion; Kidney; Life; Liver; Lung; Maternal Exposure; Measurement; Measures; Mumps; Nature; Nose; Occupations; Organ; Participant; Publishing; Research; Risk; Rubella; SARS-CoV-2 antibody; SARS-CoV-2 infection; Saliva; Sampling; Secondary Immunization; Serum; Site; Source; Specimen; Symptoms; Testing; Tetanus; Time; Toxic effect; United States; Universities; Vaccinated; Vaccination; Vaccines; antibody test; bioaccumulation; case control; consumer product; exposed human population; fire fighter; first responder; ground water; high risk; innovation; perfluorohexane; perfluorooctane sulfonate; recruit; respiratory; response; study population; surveillance study; vaccine effectiveness; vaccine-induced antibodies

PROJECT SUMMARY/ABSTRACT Infection with SARS-CoV-2 and its associated disease state, COVID-19, has resulted in over 374,000 deaths in the United States to date. Vaccines protecting against COVID-19 have recently received FDA emergency use authorization and are being administered to high-risk individuals with wider dissemination to follow. Exposure to per- or polyfluoroalkyl substances (PFAS) is associated with reduced immune response following vaccination against other infections, but its effect on COVID-19 vaccine effectiveness is not known. We have a time-sensitive opportunity to determine the effect of serum PFAS on response to COVID-19 vaccination, building on a unique study in ~2,000 healthcare workers, first responders and other essential workers in Arizona without prior COVID- 19 infection, many of whom have either recently been vaccinated or will be vaccinated in the coming months, supplemented by ~700 additional participants from a similar study in both Arizona and Florida. Our objective in this application is to determine the effects of PFAS exposure levels on COVID-19 vaccine effectiveness. Our central hypotheses are that increased PFAS serum concentrations will: 1) reduce initial SARS-CoV-2 antibody titers following COVID-19 vaccination; 2) increase the rate of longitudinal decline in antibody titers; and 3) increase the frequency of COVID-19 during a nine-month period following vaccination. The rationale for this research is that successful completion can be expected to provide new data about the immune effects of PFAS exposure. We will test these hypotheses through two regular and one exploratory specific aims: 1) Evaluate the association of serum PFAS with initial SARS-CoV-2 antibody titers following COVID-19 vaccination; 2) Evaluate the association of serum PFAS with longitudinal decline in SARS-CoV-2 antibody titers following COVID-19 vaccination; and 3) Evaluate the association of serum PFAS concentrations with frequency of COVID-19 following vaccination. For aims 1 and 2, we will select 600 of our Arizona study participants for measurement of serum PFAS following COVID-19 vaccination. As part of the study, these participants will also provide serum for measurement of SARS-CoV-2 antibodies every three months for at least nine months, and provide respiratory samples weekly for PCR testing to identify SARS-CoV-2 infection. For the exploratory aim, we will identify all COVID-19 cases following vaccination in both the Arizona and Florida study populations, and for each case select five matched controls who received COVID-19 vaccination but were not infected with SARS-CoV-2. Serum PFAS levels will be compared across the cases and controls. At study completion, we will have documented the effects of PFAS exposure on SARS-CoV-2 antibodies following COVID-19 vaccination and the frequency of COVID-19 cases following vaccination. The proposed research is significant given the potential for PFAS exposure to reduce the effectiveness of COVID-19 vaccines. The proposed research is innovative as it is the first to our knowledge to determine the association between serum PFAS levels and measures of COVID-19 vaccine effectiveness.

项目摘要/摘要 SARS-COV-2及其相关疾病状态Covid-19的感染已导致超过374,000人死亡 迄今为止的美国。防止COVID-19的疫苗最近收到了FDA紧急使用 授权并正在向具有更广泛传播的高风险个人进行管理。接触 疫苗接种后免疫反应降低有关 针对其他感染，但尚不清楚其对Covid-19疫苗有效性的影响。我们有时间敏感 确定血清PFA对COVID-19疫苗反应的影响的机会，建立在独特的基础上 在没有事先的企业 19感染，其中许多人最近已接种疫苗，或者将在未来几个月内接种疫苗， 在亚利桑那州和佛罗里达州的一项类似研究中，还补充了约700名参与者。我们的目标 该应用是为了确定PFAS暴露水平对COVID-19疫苗有效性的影响。我们的 中心假设是PFAS血清浓度增加将：1）减少初始SARS-COV-2抗体 COVID-19疫苗接种后的滴度； 2）增加抗体滴度纵向下降的速度； 3） 在疫苗接种后的9个月内增加了Covid-19的频率。理由 研究是，可以预期成功完成有关PFA的免疫作用的新数据 接触。我们将通过两个常规和一个探索性特定目的来检验这些假设：1）评估 血清PFA与COVID-19疫苗接种后初始SARS-COV-2抗体滴度的关联； 2）评估 COVID-19 疫苗接种； 3）评估血清PFAS浓度与Covid-19的频率的关联 疫苗接种后。对于目标1和2，我们将选择600位亚利桑那研究参与者进行测量 COVID-19疫苗接种后血清PFA。作为研究的一部分，这些参与者还将为 至少九个月，每三个月测量SARS-COV-2抗体一次，并提供呼吸系统 每周样品进行PCR测试，以鉴定SARS-COV-2感染。为了探索目的，我们将确定所有 在亚利桑那州和佛罗里达州研究人群中疫苗接种后的COVID-19案件，每种情况下 选择五个接收COVID-19疫苗但未感染SARS-COV-2的匹配对照组。血清 将在整个病例和对照组中比较PFAS水平。在学习完成时，我们将记录 PFAS暴露对COVID-19疫苗接种后SARS-COV-2抗体的影响和 疫苗接种后的Covid-19案件。鉴于PFA的潜力，拟议的研究很重要 暴露以降低1900疫苗的有效性。拟议的研究具有创新性，因为它是 首先，我们的知识是确定血清PFA水平与COVID-19的措施之间的关联 疫苗有效性。